Basilea Pharmaceutica has announced that the continued strong sales of Cresemba (isavuconazole, Basilea’s lead antifungal therapy) has triggered a US$30m milestone payment from Pfizer, its license partner in Europe.
Cresemba is marketed in over 70 countries, including the US, most EU member states and additional countries inside and outside of Europe. According to the latest available market data, total global in-market sales of Cresemba amounted to US$652m in the 12 months between July 2024 and June 2025, representing 27% growth year-on-year.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment